Here is the link to the Microtablet article (note
Post# of 72440
http://www.corerxpharma.com/wp-content/upload...leting.pdf
At the top of the right side col. on page 1 is this excerpt which IMO makes B-IMB even more valuable than first thought:
" If a company decides to adjust the proportion of the different APIs or release profiles during the development, formulators just have to adjust the mix inside the capsule. Subsequent generic manufacturers would face a tricky reformulation."